Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape. Click here to read more @ Renal Cell Carcinoma Pipeline Outlook
Key Takeaways from the Renal Cell Carcinoma Pipeline Report
In May 2025, Merck Sharp & Dohme LLC announced a study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.
In May 2025, Karie Runcie announced a Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
DelveInsight's Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
Discover groundbreaking developments in Renal Cell Carcinoma therapies! Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Renal Cell Carcinoma Clinical Trials Assessment
Renal Cell Carcinoma Emerging Drugs Profile
CM082: Betta Pharmaceuticals
CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.
TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.
IPI-549: Infinity Pharmaceuticals
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.
CMN-001: ColImmune
Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.
The Renal Cell Carcinoma Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.
Stay informed about the Renal Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs
Renal Cell Carcinoma Companies
AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Oral
Subcutaneous
Intravenous
Intramuscular
Molecule Type
Renal Cell Carcinoma Products have been categorized under various Molecule types such as
Bispecific Antibody
Peptides
Small molecule
Gene therapy
Product Type
Transform your understanding of the Renal Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Renal Cell Carcinoma Pipeline Report
Coverage- Global
Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies
Table of Content
Introduction
Renal Cell Carcinoma Executive Summary
Renal Cell Carcinoma: Overview
Renal Cell Carcinoma Pipeline Therapeutics
Renal Cell Carcinoma Therapeutic Assessment
Renal Cell Carcinoma – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Renal Cell Carcinoma Collaboration Deals
Late Stage Products (Phase III)
TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IPI-549: Infinity Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AVB-S6-500: Aravive Inc.
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company name
Drug profiles in the detailed report…..
Inactive Products
Renal Cell Carcinoma Key Companies
Renal Cell Carcinoma Key Products
Renal Cell Carcinoma - Unmet Needs
Renal Cell Carcinoma - Market Drivers and Barriers
Renal Cell Carcinoma - Future Perspectives and Conclusion
Renal Cell Carcinoma Analyst Views
Renal Cell Carcinoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 minutes ago
- Globe and Mail
QuantumScape Announces Timing of Second Quarter 2025 Business Results and Webcast
QuantumScape Corporation (NYSE: QS), a leader in developing next-generation solid-state lithium-metal batteries, today announced it will release its 2025 second-quarter business results after market close on Wednesday, July 23, 2025. This will be followed by a conference call at 2 p.m. Pacific Time (5 p.m. Eastern Time). Siva Sivaram, chief executive officer, and Kevin Hettrich, chief financial officer, will participate on the call. Starting today, July 9, shareholders can submit questions ( here) they would like addressed on the call. QuantumScape management will respond to a selection of the submitted questions. The company will accept questions until Tuesday, July 22, at 2 p.m. Pacific Time (5 p.m. Eastern Time). The call will be accessible live via a webcast on QuantumScape's IR Events Calendar page. An archive of the webcast will be available shortly after the call for 12 months. About QuantumScape Corporation QuantumScape is on a mission to revolutionize energy storage to enable a sustainable future. The company's next-generation batteries are designed to enable greater energy density, faster charging and enhanced safety to support the transition away from legacy energy sources toward a lower carbon future. For more information, visit
Globe and Mail
12 minutes ago
- Globe and Mail
UDR Announces Dates for Second Quarter 2025 Earnings Release and Conference Call
UDR, Inc. (the 'Company') (NYSE: UDR), a leading multifamily real estate investment trust, announced today that it will release its second quarter 2025 financial results on Wednesday, July 30, 2025, after the market closes. A conference call will be held on Thursday, July 31, 2025, at 12:00 p.m. Eastern Time. The conference call will be open to the public. During the conference call, company officers will review second quarter 2025 results, discuss recent events, and conduct a question-and-answer period. The question-and-answer period will be limited to registered financial analysts. All other participants will have listen-only capability. To participate in the webcast: Please go to UDR's website at at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software. A replay will also be available on UDR's website. To participate in the live telephone conference call, please dial one of the following numbers at least five minutes prior to the start time: The full text of the earnings release and supplemental data will be available immediately following the earnings release to the wire services on July 30, 2025, at UDR's investor relations website at About UDR, Inc. UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate properties in targeted U.S. markets. As of March 31, 2025, UDR owned or had an ownership position in 60,047 apartment homes, including 300 apartment homes under development. For over 53 years, UDR has delivered long-term value to shareholders, the best standard of service to residents and the highest quality experience for associates.
Globe and Mail
12 minutes ago
- Globe and Mail
Crown Castle Announces Second Quarter 2025 Earnings Conference Call Details
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") plans to release its second quarter 2025 results on Wednesday, July 23, 2025, after the market closes. In conjunction with the release, Crown Castle has scheduled a conference call for Wednesday, July 23, 2025, at 5:30 p.m. eastern time. A listen only live audio webcast of the conference call, along with any supplemental materials, can be accessed on the Crown Castle website at Participants may join the conference call by dialing 833-816-1115 (Toll Free) or 412-317-0694 (International) at least 30 minutes prior to the start time. All dial-in participants should ask to join the Crown Castle call. A replay of the webcast will be available on the Investor page of Crown Castle's website until end of day, Thursday, July 23, 2026. ABOUT CROWN CASTLE Crown Castle owns, operates and leases more than 40,000 cell towers and approximately 90,000 route miles of fiber supporting small cells and fiber solutions across every major U.S. market. This nationwide portfolio of communications infrastructure connects cities and communities to essential data, technology and wireless service – bringing information, ideas and innovations to the people and businesses that need them. For more information on Crown Castle, please visit CONTACTS
